La interleucina 6 en la fisiopatología de la artrirtis reumatoide

Kishimoto, 2005, Interleukin-6: from basic science to medicine. 40 years in immunology, Annu Rev Immunol, 23, 1, 10.1146/annurev.immunol.23.021704.115806 Hirano, 1986, Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin, Nature, 324, 73, 10.1038/324073a0 Hirano, 1985, Purification o homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2), Proc Natl Acad Sci U S A, 2, 5490, 10.1073/pnas.82.16.5490 Jourdan, 1990, Constitutive production of interleukin-6 and immunologic features in cardiac myxomas, Arthritis Rheum, 33, 398, 10.1002/art.1780330313 Gauldie, 1989, IFN beta 2/BSF2/IL-6 is the monocyte-derived HSF that regulates receptor-specific acute phase gene regulation in hepatocytes, Ann N Y Acad Sci, 557, 46, 10.1111/j.1749-6632.1989.tb23998.x Hirano, 1988, Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis, Eur J Immunol, 18, 1797, 10.1002/eji.1830181122 Yoshizaki, 1989, Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease, Blood, 74, 1360, 10.1182/blood.V74.4.1360.1360 Firestein, 1990, Quantitative analysis of cytokine gene expression in rheumatoid arthritis, J Immunol, 144, 3347, 10.4049/jimmunol.144.9.3347 Rose-John, 2006, Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer, J Leukoc Biol, 80, 227, 10.1189/jlb.1105674 Heinrich, 2003, Principles of interleukin (IL)-6-type cytokine signalling and its regulation, Biochem J, 374, 1, 10.1042/bj20030407 Castell, 1989, Interleukin-6. The major regulator of acute-phase protein synthesis in man and rat, Ann N Y Acad Sci, 557, 87, 10.1111/j.1749-6632.1989.tb24001.x Andrews, 2004, Anemia of inflammation: the cytokine-hepcidin link, J Clin Invest, 113, 1251, 10.1172/JCI21441 Peters, 1998, Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis, Blood, 92, 3495, 10.1182/blood.V92.10.3495 Manolagas, 1995, Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis, N Engl J Med, 332, 305, 10.1056/NEJM199502023320506 Ohshima, 1998, Interleukin 6 plays a key role in the development of antigen-induced arthritis, Proc Natl Acad Sci U S A, 95, 8222, 10.1073/pnas.95.14.8222 Finck, 1994, Interleukin 6 promotes murine lupus in NZB/NZW F1 mice, J Clin Invest, 94, 585, 10.1172/JCI117373 Serada, 2008, IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis, Proc Natl Acad Sci U S A, 105, 9041, 10.1073/pnas.0802218105 Glund, 2008, Role of interleukin-6 signalling in glucose and lipid metabolism, Acta Physiol, 192, 37, 10.1111/j.1748-1716.2007.01779.x Wallenius, 2002, Interleukin-6-deficient mice develop mature-onset obesity, Nat Med, 8, 75, 10.1038/nm0102-75 Lee, 2005, The evolving role of inflammation in obesity and the metabolic syndrome, Curr Diab Rep, 5, 70, 10.1007/s11892-005-0071-7 Veldhuis, 1995, Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer, J Clin Oncol, 13, 2585, 10.1200/JCO.1995.13.10.2585 Maini, 2006, CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, Arthritis Rheum, 54, 2817, 10.1002/art.22033 Knudsen, 2008, Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome, J Rheumatol, 35, 1277 Straub, 1997, Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs, Br J Rheumatol, 36, 1298, 10.1093/rheumatology/36.12.1298 Miyazawa, 1999, IL-6 synthesis by rheumatoid synoviocytes is autonomously upregulated at the transcriptional level, J Allergy Clin Immunol, 103, S437, 10.1016/S0091-6749(99)70159-4 Kotake, 1996, Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation, J Bone Miner Res, 11, 88, 10.1002/jbmr.5650110113 Weaver, 2006, Th17: an effector CD4 T cell lineage with regulatory T cell ties, Immunity, 24, 677, 10.1016/j.immuni.2006.06.002 Zhou, 2008, TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function, Nature, 453, 236, 10.1038/nature06878 Dominitzki, 2007, Trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells, J Immunol, 179, 2041, 10.4049/jimmunol.179.4.2041 Nadkarni, 2007, Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta, J Exp Med, 204, 33, 10.1084/jem.20061531 Wong, 2006, Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis, Arthritis Rheum, 54, 158, 10.1002/art.21537 Hata, 2004, Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice, J Clin Invest, 114, 582, 10.1172/JCI200421795 Iwanami, 2008, Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase, Arthritis Rheum, 58, 754, 10.1002/art.23222 Gabay, 2006, Interleukin-6 and chronic inflammation, Arthritis Res Ther, 8, S3, 10.1186/ar1917 Kopf, 1994, Impaired immune and acute-phase responses in interleukin-6-deficient mice, Nature, 368, 339, 10.1038/368339a0 Legendre, 2003, JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression, J Biol Chem, 278, 2903, 10.1074/jbc.M110773200 Nishimoto, 2005, Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease, Blood, 106, 2627, 10.1182/blood-2004-12-4602 Yokota, 2005, Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 52, 818, 10.1002/art.20944 Hirao M, Hashimoto J, Tsuboi H, Nampei A, Nakahara H, Yoshio N, et al. Laboratory and febrile features after joint surgery in rheumatoid arthritis patients treated with tocilizumab. Ann Rheum Dis. 2008 Jun 2. [Epub ahead of print]. doi:10.1136/ard.2008.090068 Smolen, 2008, OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial, Lancet, 371, 987, 10.1016/S0140-6736(08)60453-5 Nakahara, 2003, Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis, Arthritis Rheum, 48, 1521, 10.1002/art.11143 Paleolog, 1998, Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor and interleukin-1 in rheumatoid arthritis, Arthritis Rheum, 41, 1258, 10.1002/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1 Nishimoto, 2007, Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab, Ann Rheum Dis, 66, 1162, 10.1136/ard.2006.068064